Study Title
Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Details
Description:
The purpose of this program is to provide access to [Lu-177]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC). Patients must have received at least 1 prior androgen pathway inhibitor (ARPI) and cannot be treated by currently available drugs or clinical trials.
Sponsor:
Lantheus Medical Imaging
Contacts:
Associate Director Radioligand Clinical Applicationslnth-pnt2002-eap-info@lantheus.com
901-283-5950
Government Study Link:
NCT06033001 - Click here to see study onClinicalTrials.gov